# Molbio Diagnostics FY26 Revenue Rises 41.7% to Rs 1,446 Crore as Test-Kit Volumes Climb

> Molbio Diagnostics reported FY26 revenue of Rs 1,446 crore, up 41.7%, with test-kit volumes at 17.6 million units and FY27 growth targeted at about 25%.

- Published: 2026-10-22T02:03:39+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-22/molbio-diagnostics-fy26-revenue-growth
- Source: [NDTV Profit](https://www.ndtvprofit.com/business/molbio-diagnostics-has-spare-capacity-can-it-turn-that-into-growth-12217831)

## Key takeaways

- Molbio Diagnostics reported FY26 revenue of Rs 1,446 crore, up 41.7%, and net profit of Rs 164 crore, up 14.9%.
- Test-kit volumes rose to 17.6 million units in FY26 from 8.8 million units in FY24.
- Molbio has annual capacity for 39 million test kits and 5,400 Truenat devices, with FY26 utilisation at 58.25% and 42.30% respectively.

[Molbio Diagnostics](https://akta.pro/company-profiles/0000dma/molbio-diagnostics) reported FY26 revenue of Rs 1,446 crore, up 41.7% year on year, with test-kit volumes rising 41% to 17.6 million units. The company said net profit rose 14.9% to Rs 164 crore. Molbio makes the portable Truenat molecular testing platform and single-use test kits, and has installed more than 12,500 devices across over 90 countries.

## Molbio's FY26 Results and Truenat Kit Volumes

Molbio's revenue increased 41.7% year on year to Rs 1,446 crore in FY26, while net profit rose 14.9% to Rs 164 crore, [NDTV Profit](https://www.ndtvprofit.com/business/molbio-diagnostics-has-spare-capacity-can-it-turn-that-into-growth-12217831) reported. EBITDA increased 22.6% to Rs 328 crore, with an EBITDA margin of 22.6%. Test-kit sales reached 17.6 million units in FY26, up from 8.8 million units in FY24, a compound annual growth rate of 41%.

Truenat is a portable, battery-operated, multi-disease real-time PCR platform that delivers results in about 60 minutes. The platform has been used to conduct more than 40 million tests worldwide. Consumables accounted for 74% of product revenue in FY26 and 75% in the first quarter of FY27. Tuberculosis test kits accounted for about 70.2% of FY26 revenue and 96% of test-kit sales volume.

Molbio has annual manufacturing capacity for 39 million test kits and 5,400 Truenat devices. In FY26, capacity utilisation was 58.25% for test kits and 42.30% for devices. Management targets revenue growth of about 25% and an EBITDA margin of 24% to 25% for FY27. Annual Truenat device sales are expected to remain within the historical range of 2,200 to 2,600 units.

## Molbio's HPV Test and AI Pathology Moves

According to akta.pro [company records](https://akta.pro/company-data), Molbio launched India's first indigenous WHO-IARC-validated HPV test, Truenat HPV-HR Plus, in June 2026, with 91.5% specificity and 80.4% sensitivity for cervical cancer screening. AIIMS New Delhi collaborated on validation of the test, and ICMR institutes participated in the study alongside WHO-IARC. In February 2026, Molbio launched BactoSiA, an AI-assisted TB treatment monitoring solution, at WHX Labs World Health Expo in Dubai.

## Molbio's Stake Sales Before the Results

India Business Excellence Fund III sold 30 lakh Molbio Diagnostics shares on September 23, 2026, reducing its stake from 11.52% to 8.92%, [ScanX](https://akta.pro/news-signals) reported. The fund sold a further 23,77,627 shares on September 30, 2026, cutting its stake to 6.85%. Kotak Mahindra Mutual Fund acquired 570,000 Molbio Diagnostics shares on October 8, 2026, raising its stake to 5.4834% of voting capital.

## What Molbio Has Said About FY27

Molbio is pursuing US Food and Drug Administration submissions for its products and has secured European Union In Vitro Diagnostic Regulation Class C certification for its Truenat CT/NG test kits. Management is working to strengthen its presence in Africa and Southeast Asia while preparing to enter Europe and the US.

## Companies in this story

- [Molbio Diagnostics company profile](https://akta.pro/company-profiles/0000dma/molbio-diagnostics) · website: http://www.molbiodiagnostics.com

---
News for Agent · https://newsforagent.com/llms.txt